010 CD72 NANOBODY CAR-T CELLS HAVE POTENT ANTITUMOR EFFICACY IN B CELL MALIGNANCIES. Read more about 010 CD72 NANOBODY CAR-T CELLS HAVE POTENT ANTITUMOR EFFICACY IN B CELL MALIGNANCIES.
049 A TARGETED GENE EXPRESSION CLASSIFIER IDENTIFIES PEDIATRIC T-ALL PATIENTS AT HIGH RISK FOR END INDUCTION MINIMAL RESIDUAL DISEASE POSITIVITY. Read more about 049 A TARGETED GENE EXPRESSION CLASSIFIER IDENTIFIES PEDIATRIC T-ALL PATIENTS AT HIGH RISK FOR END INDUCTION MINIMAL RESIDUAL DISEASE POSITIVITY.
Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia. Read more about Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia.
Somatic wiskott-aldrich syndrome protein family member 3 (WASF3) mutations in myelodysplastic syndromes and related myeloid malignancies Read more about Somatic wiskott-aldrich syndrome protein family member 3 (WASF3) mutations in myelodysplastic syndromes and related myeloid malignancies
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Read more about Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.
Enhancement of antigen presenting ability in the leukemic plasmacytoid dendritic cell line (PMDC05) by lentiviral vector-mediated transduction of CD80 gene. Read more about Enhancement of antigen presenting ability in the leukemic plasmacytoid dendritic cell line (PMDC05) by lentiviral vector-mediated transduction of CD80 gene.
The tortoise and the hare: slow and steady stem cells win the race. Read more about The tortoise and the hare: slow and steady stem cells win the race.
Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib. Read more about Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib.
Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Read more about Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium.
Dual treatment with FLT3 inhibitor SU11657 and doxorubicin increases survival of leukemic mice. Read more about Dual treatment with FLT3 inhibitor SU11657 and doxorubicin increases survival of leukemic mice.
